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Drug resistance spreads through a population because (i)
parasites can survive direct treatment and/or (ii) survive
“residual” drug levels persisting from previous treatment.
High levels of drug use and long drug half-lives mean a
high proportion of the population may have residual drug
levels selecting for resistance. Field studies can quantify
this second force of resistance by estimating a window of
selection (WoS); a period of time during which drug levels
have declined sufficiently to allow new infections with
drug resistant parasites while still able to prevent infec-
tions by drug sensitive parasites. Typically this is estimated
by comparing how early different genotypes become
detectable after treatment. These WoS estimates are
widely cited and we refer to them as ‘apparent’ WoS to
denote their origin in clinical observations. In fact the
‘true’ WoS is the period in which infections bearing the
mutation can emerge from the liver and survive to pro-
duce a patent infection while sensitive parasites are killed
by residual drug concentrations. Unfortunately, it is
impossible to observe this emergence because parasites
(assuming 105 emerge) are below the microscopic limit of
detection (assumed to be 108) and so we are forced to rely
on ‘apparent’ WoS i.e., the time at which they have grown
to patency.
We use the validated mechanistic pharmacokinetic-
pharmacodynamic (PK/PD) model described in Winter &
Hastings [1] to simulate WoS for increasingly resistant
infections and to ascertain how accurately field observa-
tions estimate the ‘true’ window of selection. Observed
estimates of the WoS generally provide a good match to
the ‘true’ WoS when resistance levels are moderate to high
(i.e., increases in the half-maximal killing rate or IC50 of
10-fold or more). However, field methods may overesti-
mate it when resistance levels are low or when parasites
are able to successfully cause reinfections in the first few
days following treatment. The latter is usually accompa-
nied by high levels of resistance and hence treatment fail-
ures that should provide warnings that this effect may
occur.
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